ALFA Filings
Every announcement, straight from the exchange
Every Zydus Lifesciences merger & restructuring announcement on NSE and BSE, newest first, each with its own page.
Time
10 announcements
Zydus Lifesciences has mutually extended the closing date for its 50:50 joint venture transaction with Sunshine Healthcare Lanka Limited to December 2026.
Zydus Lifesciences Limited has incorporated a wholly owned subsidiary, Zydus Global Treasury Centre IFSC Limited, in GIFT City, Gujarat. The subsidiary has a paid-up capital of Rs. 5 Crore.
Zydus Lifesciences is acquiring the API business of Sterling Biotech for Rs.84 Crore. The deal, delayed to Sep‑30‑2026, adds fermentation‑based products to its portfolio.
Zydus Lifesciences extended the closing date for its acquisition of Sterling Biotech’s API business to September 30, 2026. The deal remains pending completion.
Zydus Lifesciences formed a 50:50 joint venture in Sri Lanka. The investment is valued at up to ₹47 Crore.
Zydus Lifesciences increased its share buyback price to ₹1,260 per share for a ₹1,100 Crore total offer. Maximum shares reduced to 87,30,158.
Zydus Lifesciences invested ₹9.02 Crore to complete its subscription in Torrent Urja 25. The company now holds a 22.06% stake in the entity.
Zydus Lifesciences approved a ₹1,100 Crore share buyback at ₹1,150 per share. The tender offer targets 95,65,217 shares, representing a significant premium to market price.
Zydus Lifesciences Limited, through its subsidiary Zydus Worldwide DMCC, incorporated a new wholly owned subsidiary named Zara Merger SUB Inc. in the USA on April 24, 2026. The new entity belongs to the pharmaceutical industry. There was no cash consideration for the incorporation.
Zydus Lifesciences incorporated a new wholly owned subsidiary, Zara Merger SUB Inc., in the United States on April 24, 2026. The entity is part of an internal group restructuring within the pharmaceutical industry. The subsidiary has not yet commenced business operations and currently reports nil turnover.